• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    8/23/22 5:41:53 PM ET
    $ABVC
    $ENDP
    $GLS
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • Minerva Neurosciences (NASDAQ:NERV) stock rose 30.1% to $5.87 during Tuesday's after-market session. Trading volume for this security closed at 1.6 million, accounting for 158.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $31.3 million.
    • NantHealth (NASDAQ:NH) shares increased by 10.54% to $0.47. The market value of their outstanding shares is at $54.1 million.
    • Regulus Therapeutics (NASDAQ:RGLS) shares rose 8.6% to $1.64. The market value of their outstanding shares is at $24.0 million.
    • Seer (NASDAQ:SEER) stock increased by 7.79% to $10.78. The market value of their outstanding shares is at $674.9 million.
    • Talkspace (NASDAQ:TALK) shares increased by 7.0% to $1.68. The company's market cap stands at $265.7 million.
    • Endo International (NASDAQ:ENDP) stock moved upwards by 6.3% to $0.33. Trading volume for this security closed at 5.6 million, accounting for 9.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $77.2 million.

    Losers

    • Reviva Pharmaceuticals (NASDAQ:RVPH) stock fell 7.4% to $1.38 during Tuesday's after-market session. Trading volume for this security closed at 134.4K, accounting for 39.3% of its average full-day volume over the last 100 days. The company's market cap stands at $25.0 million.
    • ABVC BioPharma (NASDAQ:ABVC) stock fell 6.82% to $0.82. The market value of their outstanding shares is at $26.7 million.
    • Gelesis Holdings (NYSE:GLS) stock declined by 6.37% to $1.03. The company's market cap stands at $74.7 million.
    • Sharecare (NASDAQ:SHCR) shares declined by 5.62% to $1.68. The market value of their outstanding shares is at $592.0 million.
    • Windtree Therapeutics (NASDAQ:WINT) stock fell 5.0% to $0.67. Windtree Therapeutics's trading volume hit 11.5 million shares by close, accounting for 4889.9% of its average volume over the last 100 days. The company's market cap stands at $20.3 million.
    • Phio Pharma (NASDAQ:PHIO) shares declined by 4.84% to $0.68. The company's market cap stands at $9.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $ENDP
    $GLS
    $NERV

    CompanyDatePrice TargetRatingAnalyst
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    3/5/2026Buy → Hold
    D. Boral Capital
    Talkspace Inc.
    $TALK
    12/9/2025$3.50Equal Weight
    Barclays
    Talkspace Inc.
    $TALK
    10/31/2025$5.00Hold → Buy
    Needham
    Reviva Pharmaceuticals Holdings Inc.
    $RVPH
    9/29/2025$2.00Buy
    Chardan Capital Markets
    Phio Pharmaceuticals Corp.
    $PHIO
    6/5/2025$14.00Buy
    H.C. Wainwright
    Talkspace Inc.
    $TALK
    4/3/2025$5.00Buy
    Canaccord Genuity
    Regulus Therapeutics Inc.
    $RGLS
    3/27/2025$3.00 → $6.00Equal Weight → Overweight
    Wells Fargo
    Talkspace Inc.
    $TALK
    12/9/2024$4.50Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $ABVC
    $ENDP
    $GLS
    $NERV
    SEC Filings

    View All

    SEC Form POS AM filed by ABVC BioPharma Inc.

    POS AM - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/27/26 4:30:55 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ABVC BioPharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/27/26 4:05:35 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Talkspace Inc.

    SCHEDULE 13G/A - Talkspace, Inc. (0001803901) (Subject)

    3/27/26 1:17:24 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $ABVC
    $ENDP
    $GLS
    $NERV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,700 worth of shares (5,000 units at $1.14), increasing direct ownership by 2% to 281,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    11/24/25 12:54:10 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ENDP
    $GLS
    $NERV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026

    Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the presentation of clinical data from its open‑label safety trial evaluating roluperidone co‑administered with olanzapine at the 2026 Schizophrenia International Research Society (SIRS) Annual Congress, held March 25

    3/25/26 4:05:00 PM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Publicis Health and Talkspace Partner to Improve Treatment Adherence by Addressing Gaps in Social Health and Peer Support

    NEW YORK, March 23, 2026 /PRNewswire/ -- Publicis Health, the world's most connected and data-powered health communications network, today announced a strategic partnership with Talkspace (NASDAQ:TALK) to help life sciences organizations improve treatment adherence and real-world outcomes by addressing gaps in social health and peer support, factors increasingly recognized as significant behavioral and clinical risk drivers. The collaboration leverages Wisdo Health, Talkspace's clinically validated social health and peer support platform, as a core capability within Talkspace's broader care continuum.

    3/23/26 8:03:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

    CUPERTINO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the closing on March 20, 2026 of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the "Series G Warrants") and Series H warr

    3/23/26 8:00:00 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ENDP
    $GLS
    $NERV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Prabhu Narayan

    4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

    3/20/26 5:00:47 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bhat Laxminarayan

    4 - REVIVA PHARMACEUTICALS HOLDINGS, INC. (0001742927) (Issuer)

    3/20/26 5:00:20 PM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Marketing Officer Watson Katelyn covered exercise/tax liability with 5,550 shares, decreasing direct ownership by 2% to 358,620 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    3/16/26 9:30:03 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $ABVC
    $ENDP
    $GLS
    $NERV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Reviva Pharmaceuticals downgraded by D. Boral Capital

    D. Boral Capital downgraded Reviva Pharmaceuticals from Buy to Hold

    3/5/26 8:53:11 AM ET
    $RVPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Talkspace with a new price target

    Barclays initiated coverage of Talkspace with a rating of Equal Weight and set a new price target of $3.50

    12/9/25 8:53:40 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Talkspace upgraded by Needham with a new price target

    Needham upgraded Talkspace from Hold to Buy and set a new price target of $5.00

    10/31/25 8:16:48 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $ABVC
    $ENDP
    $GLS
    $NERV
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

    King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

    10/31/25 10:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ENDP
    $GLS
    $NERV
    Financials

    Live finance-specific insights

    View All

    Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan ("NOL Plan") designed to help preserve and protect Seer's valuable income tax net operating loss carryforwards and other tax assets ("NOLs"). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not currently subject to any expiration date, represent a valuable asset of Seer and are available to reduce Seer's future federal income tax expense. The NOL Plan is similar to those adopted by numerous o

    2/26/26 4:06:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during the full year 2025Seminal customer studies published in Nature and Nature Genetics highlighting the power of the Proteograph to enable clinically relevant biomarker discovery and deep biologic insigh

    2/26/26 4:05:00 PM ET
    $SEER
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Talkspace Announces Fourth Quarter and Full Year 2025 Results

    4Q 2025 total revenue grew 29% year-over-year to $63.0 million4Q 2025 net income of $4.8 million and adjusted EBITDA1 of $6.6 million Full-year 2025 total revenue grew 22% year-over-year to $228.9 millionFull-year 2025 net income of $7.8 millionFull-year 2025 adjusted EBITDA1 grew 127% year-over-year to $15.8 million  NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Talkspace, Inc. ("Talkspace" or the "Company") (NASDAQ:TALK), today reported fourth quarter and full year 2025 financial results.   Three Months EndedDecember 31, Year EndedDecember 31,   2025 2024 2025 2024   Results % Variancefrom PriorYear Results % Variancefrom PriorYear (In thousands unless otherwise noted)Unaudited Unaudited  

    2/19/26 8:00:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $ABVC
    $ENDP
    $GLS
    $NERV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 7:15:44 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Regulus Therapeutics Inc.

    SC 13G/A - Regulus Therapeutics Inc. (0001505512) (Subject)

    11/14/24 5:46:12 PM ET
    $RGLS
    Biotechnology: Pharmaceutical Preparations
    Health Care